Towards Personalized Medicine in Bladder Cancer
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 4471
Special Issue Editor
2. Division of Molecular Oncology, Department of Urology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
Interests: cancer biology; cell culture; cell signaling; cancer biomarkers; renal cell carcinoma; urothelial carcinoma
Special Issue Information
Dear Colleagues,
Bladder cancer is the 10th most common cancer type worldwide. There were more than 573,000 new cases of bladder cancer in 2020. It is the 13th most common cause of cancer death, with an estimated more than 212,000 deaths worldwide.
Urothelial carcinoma (UC) accounts for approximately 95% of all bladder cancers. Low-grade non-muscle-invasive bladder cancer (NMIBC) is usually successfully managed with transurethral resection (TUR), and overall survival for NMIBC reaches 90%, according to some reports. However, long-term survival for muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer remains low. The standard-of-care treatment for MIBC and metastatic bladder cancer includes cystectomy with neoadjuvant/adjuvant chemotherapy, with or without radiation therapy. Platinum-based chemotherapy has been the first-line treatment for metastatic bladder cancer for more than two decades, but it is curative for only a small minority of patients. Combination therapy with methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) results in a median survival of 13–15 months. Combination therapy with gemcitabine and cisplatin (GC) has shown less toxicity than MVAC and widely substituted MVAC in clinical practice. However, the efficacy of GC is similar to that of MVAC.
Treatment options for bladder cancer have undergone a rapid change in recent years. Immune checkpoint inhibitors (ICIs), targeted therapies, and antibody–drug conjugates are now available. As bladder cancer is genetically heterogeneous, the optimization of patient selection to identify those most likely to benefit from a specific therapy is an urgent issue in the treatment of patients with bladder cancer.
Dr. Vladimir Bilim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bladder cancer (BC)
- urothelial carcinoma (UC)
- muscle-invasive bladder cancer (MIBC)
- metastatic urothelial carcinoma
- platinum-based chemotherapy
- immune checkpoint inhibitors (ICIs)
- antibody–drug conjugates
- targeted therapy
